A041910 Stock Overview
Engages in the manufacture and sale of pharmaceuticals products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Polaris AI Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,520.00 |
| 52 Week High | ₩10,860.00 |
| 52 Week Low | ₩4,810.00 |
| Beta | 0 |
| 1 Month Change | 32.86% |
| 3 Month Change | 22.08% |
| 1 Year Change | -30.11% |
| 3 Year Change | -17.81% |
| 5 Year Change | -30.37% |
| Change since IPO | 189.23% |
Recent News & Updates
Recent updates
Why EstechPharma Co., Ltd. (KOSDAQ:041910) Is A Top Dividend Stock
Apr 01
If You Had Bought EstechPharma's (KOSDAQ:041910) Shares Five Years Ago You Would Be Down 60%
Mar 06Declining Stock and Solid Fundamentals: Is The Market Wrong About EstechPharma Co., Ltd. (KOSDAQ:041910)?
Feb 07
We're Not So Sure You Should Rely on EstechPharma's (KOSDAQ:041910) Statutory Earnings
Jan 17Is EstechPharma Co., Ltd.'s (KOSDAQ:041910) 0.8% Dividend Worth Your Time?
Dec 22A Look At EstechPharma's (KOSDAQ:041910) Share Price Returns
Dec 01Shareholder Returns
| A041910 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 30.8% | -4.0% | 0.6% |
| 1Y | -30.1% | -4.4% | -7.9% |
Return vs Industry: A041910 underperformed the KR Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: A041910 underperformed the KR Market which returned -7.9% over the past year.
Price Volatility
| A041910 volatility | |
|---|---|
| A041910 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A041910's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A041910's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Jason Kim | www.polarisaipharma.com |
Polaris AI Pharma Corp. engages in the manufacture and sale of pharmaceuticals products in South Korea and internationally. It also offers its products for various therapeutic categories, such as diagnostic acid, antidiabetic, anti-depressants, and cholinergic. The company was formerly known as EstechPharma Co., Ltd.
Polaris AI Pharma Corp. Fundamentals Summary
| A041910 fundamental statistics | |
|---|---|
| Market cap | ₩99.89b |
| Earnings (TTM) | ₩989.48m |
| Revenue (TTM) | ₩63.94b |
0.0x
P/E Ratio0.0x
P/S RatioIs A041910 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A041910 income statement (TTM) | |
|---|---|
| Revenue | ₩63.94b |
| Cost of Revenue | ₩51.06b |
| Gross Profit | ₩12.87b |
| Other Expenses | ₩11.88b |
| Earnings | ₩989.48m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A041910 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 13:30 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Polaris AI Pharma Corp. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Al Eum Lee | iM Securities |
| Sung Hwan Choi | Kyobo Securities Co., Ltd |
| Kidal Bae | Shinhan Investment Corp. |